Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Chief Operating Officer | June 09, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date June 09, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 700,000 |
Ending reported balance
After 2026-06-18 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-06-09 · Exercise / conversion · Acquired 3,000 · Balance 703,000 Row 2 · 2026-06-09 · Sale · Disposed 3,000 · Balance 700,000 Row 3 · 2026-06-10 · Exercise / conversion · Acquired 5,000 · Balance 705,000 Row 4 · 2026-06-10 · Sale · Disposed 5,000 · Balance 700,000 F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 5 · 2026-06-18 · Exercise / conversion · Acquired 3,000 · Balance 703,000 Row 6 · 2026-06-18 · Sale · Disposed 3,000 · Balance 700,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-10-31 | Direct | 835,701 |
Reported balance
After 2026-06-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-06-09 · Exercise / conversion · Disposed 3,000 · Balance 835,701 F2: These options are vested in full. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-10-31 | Direct | 830,701 |
Reported balance
After 2026-06-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-06-10 · Exercise / conversion · Disposed 5,000 · Balance 830,701 F2: These options are vested in full. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-10-31 | Direct | 827,701 |
Reported balance
After 2026-06-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-06-18 · Exercise / conversion · Disposed 3,000 · Balance 827,701 F2: These options are vested in full. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2: These options are vested in full.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-025950 · form4.xml · derivative · entry 9 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 827,701 Underlying: Common Stock · 3,000 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are vested in full. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 3,000 | $6.35 | $19,050.00 |
DisclosureSEC source: 0001140361-26-025950 · form4.xml · nonDerivative · entry 6 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 3,000 | $0.75 | $2,250.00 |
DisclosureSEC source: 0001140361-26-025950 · form4.xml · nonDerivative · entry 5 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 703,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,800 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-025208 · form4.xml · derivative · entry 3 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838,701 Underlying: Common Stock · 2,800 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are vested in full. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,800 | $6.17 | $17,276.00 |
DisclosureSEC source: 0001140361-26-025208 · form4.xml · nonDerivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.18. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 2,800 | $0.75 | $2,100.00 |
DisclosureSEC source: 0001140361-26-025208 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 702,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,418 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-024929 · form4.xml · derivative · entry 6 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 841,501 Underlying: Common Stock · 6,418 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 6,418 | $6.21 | $39,855.78 |
DisclosureSEC source: 0001140361-26-024929 · form4.xml · nonDerivative · entry 4 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.11 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 6,418 | $0.75 | $4,813.50 |
DisclosureSEC source: 0001140361-26-024929 · form4.xml · nonDerivative · entry 3 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 706,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2026 Filed Jun 22, 2026 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-025950 · form4.xml · derivative · entry 8 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,701 Underlying: Common Stock · 5,000 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are vested in full. Read SEC document |
| June 10, 2026 Filed Jun 22, 2026 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 5,000 | $6.24 | $31,200.00 |
DisclosureSEC source: 0001140361-26-025950 · form4.xml · nonDerivative · entry 4 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 10, 2026 Filed Jun 22, 2026 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 5,000 | $0.75 | $3,750.00 |
DisclosureSEC source: 0001140361-26-025950 · form4.xml · nonDerivative · entry 3 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-024929 · form4.xml · derivative · entry 5 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 847,919 Underlying: Common Stock · 14,500 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 14,500 | $6.14 | $89,030.00 |
DisclosureSEC source: 0001140361-26-024929 · form4.xml · nonDerivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0597 to $6.19. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 14,500 | $0.75 | $10,875.00 |
DisclosureSEC source: 0001140361-26-024929 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 714,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2026 Filed Jun 22, 2026 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-025950 · form4.xml · derivative · entry 7 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 835,701 Underlying: Common Stock · 3,000 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are vested in full. Read SEC document |
| June 09, 2026 Filed Jun 22, 2026 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 3,000 | $6.15 | $18,450.00 |
DisclosureSEC source: 0001140361-26-025950 · form4.xml · nonDerivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Read SEC document |
| June 09, 2026 Filed Jun 22, 2026 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 3,000 | $0.75 | $2,250.00 |
DisclosureSEC source: 0001140361-26-025950 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 703,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,401 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-024449 · form4.xml · derivative · entry 6 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862,419 Underlying: Common Stock · 15,401 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 15,401 | $6.40 | $98,566.40 |
DisclosureSEC source: 0001140361-26-024449 · form4.xml · nonDerivative · entry 4 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.15 to $6.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 15,401 | $0.75 | $11,550.75 |
DisclosureSEC source: 0001140361-26-024449 · form4.xml · nonDerivative · entry 3 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,575 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-024449 · form4.xml · derivative · entry 5 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 877,820 Underlying: Common Stock · 19,575 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 19,575 | $6.13 | $119,994.75 |
DisclosureSEC source: 0001140361-26-024449 · form4.xml · nonDerivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 19,575 | $0.75 | $14,681.25 |
DisclosureSEC source: 0001140361-26-024449 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 719,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-022980 · form4.xml · derivative · entry 6 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897,395 Underlying: Common Stock · 4,000 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are vested in full. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 4,000 | $6.10 | $24,400.40 |
DisclosureSEC source: 0001140361-26-022980 · form4.xml · nonDerivative · entry 4 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 4,000 | $0.75 | $3,000.00 |
DisclosureSEC source: 0001140361-26-022980 · form4.xml · nonDerivative · entry 3 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 704,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-022980 · form4.xml · derivative · entry 5 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 901,395 Underlying: Common Stock · 3,500 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are vested in full. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 3,500 | $6.08 | $21,280.00 |
DisclosureSEC source: 0001140361-26-022980 · form4.xml · nonDerivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.04 to $6.1051. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 3,500 | $0.75 | $2,625.00 |
DisclosureSEC source: 0001140361-26-022980 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 703,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2026 Filed May 22, 2026 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,820 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-022642 · form4.xml · derivative · entry 6 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 904,895 Underlying: Common Stock · 12,820 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| May 21, 2026 Filed May 22, 2026 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 12,820 | $6.15 | $78,843.00 |
DisclosureSEC source: 0001140361-26-022642 · form4.xml · nonDerivative · entry 4 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.22. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 21, 2026 Filed May 22, 2026 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 12,820 | $0.75 | $9,615.00 |
DisclosureSEC source: 0001140361-26-022642 · form4.xml · nonDerivative · entry 3 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2026 Filed May 22, 2026 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,400 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-022642 · form4.xml · derivative · entry 5 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 917,715 Underlying: Common Stock · 9,400 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| May 20, 2026 Filed May 22, 2026 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 9,400 | $6.15 | $57,810.00 |
DisclosureSEC source: 0001140361-26-022642 · form4.xml · nonDerivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0908 to $6.2935. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 20, 2026 Filed May 22, 2026 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 9,400 | $0.75 | $7,050.00 |
DisclosureSEC source: 0001140361-26-022642 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 709,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,120 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-022235 · form4.xml · derivative · entry 6 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 927,115 Underlying: Common Stock · 9,120 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 9,120 | $6.37 | $58,094.40 |
DisclosureSEC source: 0001140361-26-022235 · form4.xml · nonDerivative · entry 4 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.3002 to $6.4119. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 9,120 | $0.75 | $6,840.00 |
DisclosureSEC source: 0001140361-26-022235 · form4.xml · nonDerivative · entry 3 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 709,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-022235 · form4.xml · derivative · entry 5 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 936,235 Underlying: Common Stock · 200 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 200 | $6.62 | $1,324.00 |
DisclosureSEC source: 0001140361-26-022235 · form4.xml · nonDerivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.6102 to $6.6215. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 200 | $0.75 | $150.00 |
DisclosureSEC source: 0001140361-26-022235 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-021889 · form4.xml · derivative · entry 6 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 936,435 Underlying: Common Stock · 13,100 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 13,100 | $6.65 | $87,115.00 |
DisclosureSEC source: 0001140361-26-021889 · form4.xml · nonDerivative · entry 4 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.58 to $6.85. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 13,100 | $0.75 | $9,825.00 |
DisclosureSEC source: 0001140361-26-021889 · form4.xml · nonDerivative · entry 3 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 713,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,580 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-26-021889 · form4.xml · derivative · entry 5 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 949,535 Underlying: Common Stock · 15,580 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are vested in full. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 15,580 | $6.91 | $107,657.80 |
DisclosureSEC source: 0001140361-26-021889 · form4.xml · nonDerivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.8326 to $7.28. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 15,580 | $0.75 | $11,685.00 |
DisclosureSEC source: 0001140361-26-021889 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2025 Filed May 15, 2025 00:21 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-25-019053 · form4.xml · derivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 965,115 Underlying: Common Stock · 50,000 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are vested in full. Read SEC document |
| April 01, 2025 Filed May 15, 2025 00:21 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 50,000 | $0.75 | $37,500.00 |
DisclosureSEC source: 0001140361-25-019053 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.